A group of Grifols shareholders, including Flat Footed LLC, Mason Capital Management LLC and Sachem Head Capital Management LP, wants a seat on the drugmaker’s board, Bloomberg’s Jorge Zuloaga and Clara Hernanz Lizarraga report. The investors, who manage a combined interest of 7.7% of class A shares of the company, said in a letter to Grifols’ board that they are seeking to exercise their statutory right to name a director, the authors note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Grifols postpones Capital Markets Day until further notice
- Brookfield in talks to join buyout of Grifols, Bloomberg reports
- Brookfield in talks to join sovereign funds in Grifols bid, Bloomberg says
- Grifols receive FDA clearance of IND application for Phase 1 trial of GIGA-2339
- Grifols restates financials for first half of 2024 due to incorrect accounting